Drug Trial Radar · NCT05477563
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
Last checked: Nov 19, 2026Latest source record: Mar 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
26
Planned (sponsor's estimate)
Start
Aug 2, 2022
Primary completion
Jun 9, 2027
Study completion Jun 9, 2027
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- First posted
- Jul 28, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-dose, open-label study in participants with transfusion-dependent β-thalassemia (TDT) or severe sickle cell disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) using CTX001.
Conditions
- Beta-Thalassemia
- Thalassemia
- Hematologic Diseases
- Genetic Diseases, Inborn
- Hemoglobinopathies
- Sickle Cell Disease
- Sickle Cell Anemia
Interventions
CTX001Biological
Administered by intravenous (IV) infusion following myeloablative conditioning with busulfan
Primary outcomes
What the sponsor says the trial is designed to measure.
- Fetal Hemoglobin (HbF) Concentration Over TimeTime frame: Up to 12 Months After CTX001 Infusion
- Total Hemoglobin (Hb) Concentration Over TimeTime frame: Up to 12 Months After CTX001 Infusion
Locations
6 sites in 4 countries. Site status is shown where the registry gives one.
New York Presbyterian Hospital - Morgan Stanley Children's Hospital
New York, New York · Recruiting
Levine Children's Hospital - Hematology
Charlotte, North Carolina · Recruiting
TriStar Medical Group Children's Specialists - Pediatric Oncology
Nashville, Tennessee · Recruiting
University Hospital Dusseldorf - Department of Pediatric Oncology, Hematology and Clinical Immunology
Düsseldorf, Germany · Recruiting
IRCSS Ospedale Pediatrico Bambino Gesu - Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica
Rome, Italy · Recruiting
King Faisal Specialist Hospital & Research Centre - Riyadh - Hematology
Al Mathar Ash Shamali, Saudi Arabia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.